LOS GATOS, Calif., Jan. 20, 2026 /PRNewswire/ – In the pivotal clinical trial of their technology, researchers at Orlucent®, Inc. have confirmed the accuracy of the company’s Skin Fluorescent Imaging (SFI) System, a non-invasive, hand-held molecular imaging device for the direct, on-the-skin, point-of-care assessment of suspicious moles and early detection of melanoma-related activity. The results of the study conducted by Orlucent, a biotechnology company developing solutions for the non-invasive detection of melanoma activity, were published in the February edition of the peer-reviewed Journal of the American Academy of Dermatology (JAAD) International.